0,1% drops - nasal decongestant 10 ml

Product Description

Nasal decongestant useful in cases of acute catarrhal rhinitis and pharyngitis, allergic rhinitis, and acute sinusitis.

Composition

Active ingredients
1 ml of solution contains 1 mg of naphazoline nitrate.

Excipients
Sodium chloride, disodium edetate, sodium phosphate monobasic dihydrate, concentrated phosphoric acid, benzalkonium chloride, purified water.

Dosage

Adults: 2–3 drops in each nostril, 2–3 times a day.
Pediatric population: The medicine is contraindicated in children under 12 years of age.

Strictly follow the recommended doses. A higher dosage of the product, even if taken topically and for a short period of time, can result in serious systemic effects. If a complete therapeutic response is not achieved within a few days, consult your doctor. In any case, treatment should not be continued for more than a week.

Contraindications

Hypersensitivity to the active substance or to any of the excipients.
Severe heart disease and arterial hypertension.
Glaucoma.
Hyperthyroidism.
The medicine is contraindicated in children under 12 years of age.
Do not administer during and in the two weeks following therapy with antidepressant drugs.

Warnings and precautions

Use with caution in the elderly and in those with prostatic hypertrophy due to the risk of urinary retention. In patients with cardiovascular disease, especially those with hypertension, the use of nasal decongestants should be subject to a doctor's judgment on a case-by-case basis. Prolonged use of vasoconstrictors can alter the normal function of the nasal mucosa and paranasal sinuses, possibly leading to drug addiction. Repeated applications over a long period of time may be harmful. Benzalkonium chloride (BAC), contained as a preservative in RINAZINA nasal drops and nasal spray, especially when used for long periods, can cause swelling of the nasal mucosa. If such a reaction is suspected (persistent nasal congestion), a nasal medicine without BAC should be used, if possible. If such nasal medicines without BAC are not available, another dosage form should be considered. May cause bronchospasm. Use of topical products, especially if prolonged, may cause nasal congestion. may cause sensitization phenomena; in this case, treatment should be discontinued and, if necessary, appropriate therapy instituted. Rare cases of posterior reversible encephalopathy/reversible cerebral vasoconstriction syndrome have been reported with the use of sympathomimetic drugs, which include naphazoline. Reported symptoms include sudden onset of severe headache, nausea, vomiting, and visual disturbances. Most cases improve or resolve within a few days following appropriate treatment. Use of naphazoline should be discontinued immediately and a doctor should be consulted if signs and/or symptoms of posterior reversible encephalopathy/reversible cerebral vasoconstriction syndrome occur.

Interactions

The drug may interact with antidepressant drugs.

Side effects

The product may interact with antidepressant drugs.

Undesirable effects

The product may interact with antidepressant drugs. determine local rebound phenomena of sensitization and congestion of the mucous membranes. Due to rapid absorption of naphazoline through inflamed mucous membranes, systemic effects consisting of arterial hypertension, reflex bradycardia, headache, and urinary disorders may occur.

Pregnancy and breastfeeding

During pregnancy and breastfeeding, RINAZINA should be used only after consulting your doctor and evaluating the risk/benefit ratio in your case.

Format

10 ml bottle.